Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -201.89% is 178% below its 5-year average of -72.72%, near the low end of its 5-year range (-201.89%–-40.64%).
77.64% below its 12-month average of -113.65%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -60.21%.
RETURN ON ASSETS (ROA)
-201.89%
RETURN ON ASSETS (ROA) AVG TTM
-113.65%
RETURN ON ASSETS (ROA) AVG 3Y
-83.24%
RETURN ON ASSETS (ROA) AVG 5Y
-72.72%
RETURN ON ASSETS (ROA) AVG 10Y
-67.58%
RETURN ON ASSETS (ROA) AVG 15Y
-51.54%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-77.64%
CURRENT VS 3Y AVG
-142.53%
CURRENT VS 5Y AVG
-177.63%
CURRENT VS 10Y AVG
-198.73%
CURRENT VS 15Y AVG
-291.75%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.47%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
-562.59%
vs the sector median at left
Karyopharm Therapeutics Inc.
Market Cap
$15.10M
Return on Assets (ROA)
-201.89%
TTM Avg
-113.65%
3Y Avg
-83.24%
5Y Avg
-72.72%
Market Cap
$15.15M
Return on Assets (ROA)
-41.18%
TTM Avg
-60.23%
3Y Avg
-53.11%
5Y Avg
-40.22%
Market Cap
$15.58M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$14.53M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.83M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
Market Cap
$14.37M
Return on Assets (ROA)
-15.57%
TTM Avg
-20.73%
3Y Avg
-20.84%
5Y Avg
-41.87%
Market Cap
$14.15M
Return on Assets (ROA)
-32.53%
TTM Avg
-31.07%
3Y Avg
-30.77%
5Y Avg
-29.89%
Market Cap
$16.08M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$13.83M
Return on Assets (ROA)
-123.23%
TTM Avg
-153.35%
3Y Avg
-205.77%
5Y Avg
-166.29%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $15.10M | -201.89% | -113.65% | -83.24% | -72.72% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.15M | -41.18% | -60.23% | -53.11% | -40.22% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.58M | -213.77% | -110.51% | -93.41% | -68.22% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.53M | N/A | N/A | N/A | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.83M | -38.41% | -84.87% | -95.12% | -75.66% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.37M | -15.57% | -20.73% | -20.84% | -41.87% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.15M | -32.53% | -31.07% | -30.77% | -29.89% |
| BioCardia, Inc. (BCDA)vs › | $16.08M | -154.34% | -227.23% | -240.86% | -184.63% |
| Vyome Holdings, Inc. (HIND)vs › | $13.83M | -123.23% | -153.35% | -205.77% | -166.29% |
| IN8bio, Inc. (INAB)vs › | $13.71M | -85.85% | -102.78% | -95.22% | -76.09% |
ROA
-201.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -180.82% |
| 2024-12-31 | -46.48% |
| 2023-12-31 | -59.52% |
| 2022-12-31 | -46.15% |
| 2021-12-31 | -40.64% |
| 2020-12-31 | -62.70% |
| 2019-12-31 | -67.67% |
| 2018-12-31 | -52.29% |
| 2017-12-31 | -71.54% |
| 2016-12-31 | -60.75% |
| 2015-12-31 | -54.85% |
| 2014-12-31 | -34.39% |
| 2013-12-31 | -21.45% |
| 2012-12-31 | -1211.90% |
| 2011-12-31 | -142.73% |
